Method for optimising vascular wall activity in patients with degree i-ii hypertension associating metabolic syndrome suffered eye vessel thrombosis

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cardiology and angiologia, and can be used for optimising vascular wall activity in patients with degree I-II arterial hypertension (AH) associating metabolic syndrome (MS) suffered eye vessel thrombosis. That is ensured by introduction of the preparations pioglitazone and amlodipine with underlying an individually prescribed hypocaloric diet and graduated physical exercises. The hypocaloric diet is calculated in kcal by formula: for women of 18-30 years old - (0.0621 × body weight, kg + 2.0357) × 240, of 31-60 years old - (0.342 × body weight, kg + 3.5377) × 240, over 60 years old - (0.0377 × body weight, kg + 2.7545) × 240, for men of 18-30 years old - (0.0630 × body weight, kg + 2.8957) × 240, of 31-60 years old - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years old - (0.0491 × body weight, kg + 2.4587) × 240. The graduated physical exercises represent morning hygienic gymnastics, therapeutic exercises and graduated physical exercises throughout a day. The preparations pioglitazone 30 mg and amlodipine 10 mg are introduced once a day in the same time. The therapy is performed for 4 months.

EFFECT: method provides correction of reduced vascular wall function in the patients with degree I-II AH associating MS suffered eye vessel thrombosis for 4 months and allows avoiding vascular complications in such patients.

1 dwg, 1 tbl, 2 ex

 

The invention relates to medicine, namely to cardiology and angiology.

Analogues of the proposed method for optimizing the activity of blood vessels in patients with arterial hypertension (AH) I-II degree in the metabolic syndrome (MS)who have had blood clots in the eye, does not exist.

There is information on the use of a low-calorie diet (Savelyeva L. Modern approaches to treatment of obesity. // The doctor, 2000, No. 12 - p.12-14; Kadyrov, BC, Salhanov B.A. Nutrition in obesity. Alma-ATA, Kazakhstan, 1990) or physical training (V. Moshkov. Exercise in obesity. M, Medicine, 1976. - 56 S.) in patients with various components of MILLISECONDS.

In patients with MS for lowering blood pressure are often assigned valsartan. For the correction of insulin resistance in patients hypertension I-II degree when the MS is assigned to pioglitazone. However, never before medical complex, consisting of a low-calorie diet, exercise stress, drugs pioglitazone and amlodipine has been used in patients with arterial hypertension I-II degree with MS who have had blood clots in the eye, to correct their vasaputi.

The aim of the invention is the correction of the attenuation functions of blood vessels in patients with arterial hypertension I-II degree with MS who have had blood clots in the eye.

The essence of the proposed method is that the correction of the attenuation functions of blood vessels b is determined as being hypertension I-II degree at MS after thrombosis eyes, 4 months is assigned to a low-calorie diet, measured static and dynamic exercise, the drug pioglitazone at a dose of 30 mg 1 time per day and amlodipine 10 mg 1 time per day.

The method allows to adjust the weakening of the functions of blood vessels in patients with arterial hypertension I-II degree with MS who have had blood clots in the eye, within 4 months. Subject to the subsequent recommendations of the proposed method can be maintained at a normal level functions of the vascular wall, which will significantly improve the quality of life of patients with arterial hypertension I-II degree with MS who have had blood clots in the eye, to reduce their pathological burden, reduce the number of cases of temporary disability, to accelerate and improve the quality of patient treatment, to exclude disability, as well as extend the life and reduce mortality of patients with arterial hypertension I-II degree with MS who have had blood clots in the eye from a heart attack and stroke, excluding re-thrombosis of vessels of the eye.

The inventive method is carried out as follows.

To diagnose weakening of the functions of blood vessels sick AG I-II degree with MS who have had blood clots in the eye, is the next examination.

Antiaggregatory activity of the vascular wall is determined according to the method (baluda VP, Lukyanova TI, Baluda M. Method for the determination of antiaggregatory activity of the blood vessels of man.// Laborde. Case, 1983. No. 6. - p.17-20). The basis of this method is the calculation of the degree of inhibition of platelet aggregation in plasma obtained from the blood after a temporary venous occlusion.

On the shoulder of vessels which have not been manufactured blood sampling is applied to the cuff of the sphygmomanometer and creating pressure by 10 mm Hg above systolic. After 3 min produced the capture of 9 ml of blood in 1 ml of 3.8% solution of sodium citrate. It immediately centrifuged 5 min at 1000 rpm to obtain platelet-rich plasma. The plasma was aspirated with a pipette and immediately placed in melting ice, where they were kept until the beginning of the research. Again the sample was centrifuged 20 min at 3000 rpm to obtain estramboticos plasma. After counting the number of platelets in platelet-rich plasma obtained prior to venous congestion (described in detail below), it was diluted with platelet-poor plasma (Betp)taken before (1 sample) and after (2 samples) venous stagnation to a concentration of 200,000 platelets/µl. The mixture was shaken and incubated for 10 minutes at 20-22°C. Then held platelet aggregation (AT) with collagen (dilution 1:2 primary suspension) on the glass.

Assessment AT for this research is performed in the following way (Shitikova A.S. IN kN.: Hemostasis. Physiological mechanisms, principles of diagnostics of the main forms hemorragias the diseases. Edited Yea, Lpparam. SPb.: 1999. 49-52).

The blood is taken with sodium citrate 3.8% in the ratio of 9:1, centrifuged 5 min at 1000 rpm to obtain platelet-rich plasma (BTP). Part of the plasma is taken, and the remainder centrifuged at 3000 rpm for 20 min, receiving platelet-poor plasma (Betp). BTP standardise the number of platelets by dilution of the original BTP autologous sample BTP (obtained prior to venous stagnation - 1-I sample-or post - 2nd test) up to 200·109/L. the Concentration of blood platelets in the original BTP is calculated in the camera Goriaev (50 large squares). The volume mix BTP and Betp determined by the formula:

VBetp=VBTP·[(N/200000)-1],

where VBetp- the volume of platelet-poor plasma,

where VBTP- the volume of platelet rich plasma,

N is the number concentration of platelets in the original BTP (cells/µl).

Selected standardized volume of plasma on a glass slide cause of 0.02 ml of plasma and other pipette 0,02 ml R-RA inducer of collagen in the standard concentration (dilution 1:2 primary suspension). Glass wand mix plasma with inductors and include a stopwatch. The mixture is stirred so that the liquid held a circle with a diameter of about 2 cm

Shaking the glass in a circular motion in transmitted light illuminator, the and black background is watched through a magnifying glass for the occurrence of aggregates. With the appearance of distinct units, the enlightenment of the solution and the adhesion of some units to the glass stopwatch off, fixing the time of platelet aggregation.

The reaction is repeated 2-3 times in the 1st and 2nd sample, finding for each of the arithmetic mean value.

The degree of inhibition of platelet aggregation after venous congestion is judged antiaggregatory activity of blood plasma, due to the arrival of a blood of prostacyclin from vascular wall. Index antiaggregatory activity of the vascular wall (IAAS) in the study AT the glass was calculated by the formula:

Normal values for collagen can be considered IAAS 1,50-1,60.

The definition of anti-platelet properties of the vascular wall that are dependent on the production of substances that activates antithrombin III, assessing its basal level before and after the temporary metered ischemia wall of the vein below (Barkagan SS, Momot A.P. bases of diagnostics of disorders of hemostasis. M., 1999, 214 S.).

The principle of the method is based on detecting the reduction of the activity (in the absence of heparin) plasma anti-thrombin III (AT III), which is determined by the ability of the investigated plasma to inactivate thrombin, to the pretreated sorbent heparin, then subjected to heat defibrinate and mix with standard what kolichestvo thrombin. After incubation of the mixture in it determine the residual coagulation activity of thrombin. The level of reduction of the activity of thrombin in percent from the norm estimate the activity of AT III in the plasma.

Use the following reagents. 1. Tris-HCl buffer 0.05 M, pH of 7.4. 2. A solution of thrombin in buffer: 0.2 ml of a solution should minimize 0.3 ml of 0.4% solution of fibrinogen for 15-16 seconds. The working solution of thrombin is prepared in a plastic or silikonizirovannoj tube, stored at room temperature and used in the test on the day of the study. 3. Sorbent heparin Jasonb-1 (firm "Technology Standard"). 4. A freshly prepared solution of fibrinogen at a concentration of 3.5-4.0 g/l, which is used for testing residual activity of thrombin. May be replaced with a solution of fibrinogen normal platelet-poor citrate plasma, diluted with buffer 2 times. 5. Fresh citrate platelet-poor plasma obtained from 6-8 healthy people, or freeze brand, with the known activity of AT III, which is used to construct a calibration graph.

The research material is citrate platelet-poor plasma.

For the preparation of sorbed and defibrinating plasma in a test tube and mixed with 10 mg of sorbent heparin with 1.0 ml of the investigated plasma. Constantly shaking the test tube, mix the contents ol the room temperature for 8 min, excluding foam and sediment at its bottom. After that, the mixture was centrifuged for 2 min at 1000-1500 rpm Plasma in nadeshiko transferred into a clean tube and defibrinated in a water bath at +56°C for 6 min, then centrifuged at 3000 rpm for 10 min, remove the supernatant portion and explore within the first 2 hours

The course definition. In test tube add 0.4 ml of the working solution of thrombin and heat it in a water bath at +37°C for 2 minutes Then add 0.1 ml of the investigated adsorbed and defibrinating plasma include stopwatch. After 2 minutes (exactly!) 0.2 ml of the mixture is transferred into a test tube with 0.3 ml of a solution of fibrinogen (or diluted normal plasma), pre-warmed to +37°C. Immediately include stopwatch and record the clotting time.

On the calibration curve to find the activity of AT III in percent. The calibration curve carried out as follows. The plasma of healthy people are defibrinating, as described above. Then from preparing cultivation to prepare the calibration curve in accordance with table 1.

Table 1
The scheme of preparation of dilutions of plasma to construct a calibration curve for determining the active is STI AT III
The number of breedingPlasma+bufferThe activity of AT III, %
1Plasma without buffer100
20.2 ml+0.2 ml50
30.1 ml+0.3 ml25

With each of the dilutions to determine the clotting time according to the above method. All the measurements were carried out three times, calculate the average result. When constructing a calibration curve on a logarithmic ordinate axis delay the clotting time in seconds on the x-axis is the activity of AT III in % in accordance with the above dilutions. A sample calibration curve is shown in the drawing.

A calibration curve for one type and one series of thrombin and buffer build once. Periodically inspects only the activity of the working solution of thrombin.

In a normal venous occlusion activity of AT III is 85-115%. When blood samples are taken after the temporary venous occlusion, as described in the method evaluation antiaggregatory activity of the vessels, and defining AT III it is possible to indirectly evaluate the level of synthesis in the vessel wall tissue activators AT III. The piano is not a temporary venous occlusion activity of AT III rises and falls within the boundaries of 120-143%. Calculates the index of synthesis activators AT III vessels (ISAAC) by dividing the value of the activity of AT III on the background of venous occlusion on the value of AT III without it. In norm it is 1,20-1,45.

The activity of the synthesis of tissue plasminogen activators time of lysis euglobulin clot before and after the temporary venous occlusion was evaluated as follows.

The principle of the method consists in depositing euglobulin fraction of the plasma, the main inhibitor of fibrinolysis, refers α2-antiplasmin remain in the supernatant portion and removed. So euglobulin lysis reflects the activity of fibrinolysis in conditions of exclusion inhibitory effect of antiplasmin. Its rate reflects mainly the amount of plasminogen in the plasma and the degree of its activation. Determine the time of spontaneous lysis of the clot derived from euglobulin fraction of the plasma by adding to it a solution of calcium chloride.

Use the following reagents 1. 1% solution of acetic acid. 2. 0,277% solution of calcium chloride. 3. The Michaelis buffer or Tris-NA buffer, M, pH 7.3 to 7.4.

The research material is citrate platelet-poor plasma before and after the temporary venous occlusion.

The course definition. To obtain euglobulin faction to 8.0 ml of distilled water is added 0.15 ml of 1% acetic acid and 0.5 ml of investigated is lazmi. After a 30-minute cooling the mixture in the refrigerator at +2-8°C euglobulin precipitated by centrifugation at 1500 rpm for 7 minutes the Supernatant is drained, the drain tube rollover on filter paper. Sediment euglobulin diluted in 0.5 ml of buffer and placed in a water bath (+37°C). Then, without removing the tube from the bath, add 0.5 ml of a solution of calcium chloride, gently mixed by shaking the tube (not shaking!), include stopwatch and incubated in a water bath at +37°C. Record the time from the moment of addition of calcium chloride to dissolve the clot.

The results are expressed in minutes. Normal spontaneous lysis euglobulin clot is 180-240 minutes After the temporary venous occlusion time of lysis is reduced, while in the borders 126-170 min. by dividing the value of the duration of spontaneous lysis euglobulin clot to occlusion by the value after the calculated index fibrinolytic activity of the vascular wall (IFAS), the norm is equal 1,40-1,50.

Each laboratory needs to be examined group of healthy people in order to find the average normative values with the calculation of S2in all three methods for subsequent calculations.

By each method in each patient for greater accuracy diagnostic test is done 3-4 times and calculates the average of the values, which are used in subsequent calculations and the calculation of S2.

To determine the individual weight of the investigated parameters in vascular patients and calculation of common antithrombotic potential of the vessels was applied multivariate analysis system that allows you to translate the multidimensional quantitative characteristics of the process under investigation is not comparable absolute values in comparable relative values (methods of morphometric and statistical analysis in morphological studies. Comp. Mwhoa, Baglow, V. Arkhipov, etc., Kuibyshev,1982.-47 C.). The calculation was carried out according to the formulas:

Xj- analyzed parameter, X0- regulatory parameter, Xj- the relative difference.

Pi is the weight coefficient (influence), and is a constant factor (in our research and=0,1), σj- standard deviation of values of Xjin relative units:

Si2the variance of the investigated parameter Xini- the number of observations in the definition of Xi, S02- regulatory dispersion parameter X0n0- the number of observations in the definition of X0.

XBi RFP is - amount integrally characterize the process within the specified time (in relative units)is the total antithrombotic potential of vessels (oaps).

The combined application of the described methods with subsequent processing of the obtained values IAAS, ISAAC and IFAS system multifactor analysis to determining the General antithrombotic potential vessels (XBi oops) Norma 0,201 and above. The risk of weakening the antithrombotic activity of vessels observed at XBi oopsfrom - 0.200 to 0,070. When the value of XBi oopsfrom 0,069 and below, you should immediately treat patients according to the claimed method.

To create a negative energy balance in the body, patients are advised individually selected low-calorie diet.

Calorie intake is calculated in kcal individually for each patient hypertension I-II degree with MS who have had blood clots in the eye, according to the formula:

for women 18-30 years (0,0621×body weight (kg)+2,0357)×240,

31 - 60 years (0,0342×body weight (kg)+3,5377)×240,

over 60 years of age (0,0377×body weight (kg)+2,7545)×240,

for men 18-30 years (0,0630×body weight (kg)+2,8957)×240,

31 - 60 years (0,0484×body weight (kg)+3,6534)×240,

over 60 years of age (0,0491×body weight (kg)+2,4587)×240.

The resulting value remains unchanged with minimal physical exertion, noheda by a factor of 1.3 at a moderate and 1.5 at high physical activity (usually in patients with hypertension I-II degree with MS who have had blood clots in the eye, physical activity level low).

It is recommended that 3 main meals and 2 intermediate. It is recommended that the following distribution of daily calories: Breakfast - 25%, 2nd Breakfast - 10%, lunch - 35%, tea - 10%, dinner - 20%.

To compile menu the patient uses a special table with the instructions of the chemical composition and caloric content of products, given that the main sources of energy: protein (1 g contains 4 kcal), fat (9 kcal), carbohydrates (4 kcal) and alcohol (7 kcal).

The second component of the proposed method is feasible regular physical exercise.

In real life you can implement the three forms of physical activity: 1) morning hygienic gymnastics (charging); 2) health care gymnastics; 3) fractional exercise during the day.

1. Morning hygienic gymnastics (charging)

Morning gymnastics should do after waking up to Breakfast in a ventilated room. Under the influence of training the body is released from the state of inhibition of the physiological processes taking place during sleep.

The sequence of the exercises involves the alternation of load on different muscle groups (arms, legs, body). Exercises are performed with gradually increasing ek is corsia breath, tensile, limited use of power conditions. Breathing exercise should be free, rhythmic, without delay, mainly through the nose; the exhalation should be longer than the inhale (breath in 2-3 sec, exhale 3-5).

In good health the load, you can increase the number of repetitions faster, increase range of motion and shorter pauses between exercises.

When fatigue should reduce the load, increase the duration of pauses between exercises, to fill their quiet breathing.

After gymnastics, you must go to the rubbing or take a shower.

Morning exercises should evoke a sense of vitality, increase activity, improve well-being and health.

If you feel unwell, develop shortness of breath or pain in the heart and behind the sternum should be temporarily suspend classes and consult a doctor.

During the day, sick AG I-II degree with MS who have had blood clots in the eyes, recommended treatment and preventive exercises. Depending on the initial fitness may apply at the beginning of the lightweight option, physical activity, and subsequently enhanced option.

2. Complexes of preventive and curative gymnastics

2.1. The lightweight version of preventive and curative gymnastics

Exercise 1. Standing. The quiet walk with gradual is authorized by the acceleration and deceleration 1-2 minutes During exercise the gradual deepening of the breath.

Exercise 2. Circular motion in the shoulder joints. When breeding - breath, when the note - exhale with a slight tilt of the torso and retraction of the abdominal wall 6-8 times. The fingers touch the shoulders, elbows close to the torso.

Exercise 3. Standing, hands on his belt. Alternately shifting the weight of the body from one foot to the other with a small bending the legs at the knee joint without lifting the feet from the floor. Exercise done 10-16 times with the muscles of the legs.

Exercise 4. Standing, feet apart at shoulder width, hands on his belt. Bending the trunk forward, touch right hand to left toe. 4-6 times alternately. When straightened position - breath, when the tilt - exhale. To look ahead.

Exercise 5. Standing with arms along the body. At the same time to take straight arm and one leg to the side with alternating lead leg. 4-6 times in each direction in turn. A wave of the hands and feet, breathe freely, do not delay.

Exercise 6. Standing, feet apart, hands in front of chest with palms down. With a turn of the body to dissolve hand in hand with turning the palms up - breath. To return to the original position with a small tilting forward, exhale. 3-5 times in each direction in turn. Breathing to harmonize with the movement of hands and body. By the end of exhalation to engage the wall of the abdomen.

Exercise 7. Standing, hands is free. The walk free -1 min, then with high flexion of the hips - 10-20 movements with subsequent transition to a peaceful walk 1-2 minutes Breathing rhythmic, medium depth.

Exercise 8. Sitting on the edge of the chair, hands on the waist. The bowing of the back and bending forward of the body. Repeat 6-10 times. Breathing is not to delay.

Exercise 9. Sitting on the edge of the chair, the emphasis tassels on the edge of a chair, and your feet slightly in front of the chair. Squats with a focus hands on the edge of a chair - 4-6 times. When you squat exhale.

Exercise 10. Standing sideways to the back of the chair to hold it with one hand. Swing free straight arm with leg pulling back. To return to the original position. Repeat 4-6 times for each leg and arm. Breathing is not to delay.

Exercise 11. Standing, legs apart widely, hands on waist. Turns the body right and left - 6-10 times alternately. The head does not turn, to look forward.

Exercise 12. Standing, feet together, hands down. Move the hands to the sides, inhale, bend the leg at the knee and pressed his hands to his stomach exhale. 3-5 times each leg alternately. Strive to maintain balance; on the exhale, draw your abdomen.

Exercise 13. Standing, feet together, hands down. The side slopes of the case with flexion of the opposite hand ("pump"). Breathing is not to delay, to strive for greater excursion of movement.

Exercise 14. Standing. The quiet walk with even the stomach is of average depth of 1-2 minutes

Exercise 15. Lying on the Mat to put under your head with a pillow. Go to a half-sitting position and bent to hug the hips, exhale, return to the starting position and inhale. Breath hold. Strive in a semi-sitting position to maintain balance. Run 4-6 times.

Exercise 16. Lying down, arms at sides, legs apart. A semi-circular motion right straight leg to the left with the rotation of the pelvis - exhale, return to the starting position and inhale. 3-5 times in each direction. Alternately left and right, with the greatest possible excursion movement of the leg, keeping the emphasis brushes the floor.

Exercise 17. Sitting on the floor; a) to stand on all fours; b) to move into position on his knees; hands up - breath, torso, and hands to take back - exhale. When the tilt pull the stomach. Repeat 4-6 times; d) to go into a standing position, and son-in-law in the supine position; (e) self-massage of the abdomen small polukrugom movements clockwise 1-2 min Rest 2 min; W) quiet breathing; C) exercise the protrusion (calm) and retraction (active) abdominal wall. The retraction of the abdomen combined with exhale through the mouth. Repeat 4-6 times.

Exercise 18. Standing with arms bent. Energetic walking on the spot or area of high flexion of the hips and waving of hands - 20-30 steps. Breathing is not to delay.

Exercise 19. Sitting on a chair, legs apart, hands on talieri rest against the edge of a chair. The circular motion of the pelvis with the retraction of the abdomen when moving the pelvis back. 4-6 times in each direction.

Exercise 20. Standing. A peaceful walk with the breath of the average depth of 2-3 minutes

When the source sufficient trained or arising in the course of the practice of tolerance to physical loads you can use the following set of exercises.

2.2. Enhanced preventive and curative gymnastics

Exercise 1. Standing. The quiet walk with rubbing the palms of the thorax, abdomen, lower back. Runs 1-2 minutes

Exercise 2. Standing, hands down. Simultaneous bending with tension and free "throwing" hand forward, sideways and upwards of 12-16 times. When you bend exhale, when the alignment of breath.

Exercise 3. Standing, hands on waist, legs shoulder-width apart. Lateral motion of the pelvis to the right and left, back and forth. Is 6-10 times alternately. Breathe freely.

Exercise 4. Standing, feet shoulder-width apart, hands pubescent. Circular motion direct hand in the shoulder joints, 6-10 times with a maximum excursion, breathing, do not delay.

Exercise 5. Standing, hands in front of chest, bent at the elbows. Walking with high flexion of the hips, with a touch of the hand. 6 to 10 times for each leg alternately. Motion of energetic, hip flexion exhale through the mouth.

Exercise 6. The quiet walk 1-2 minutes

Exercise 7. Sitting n the edge of the chair, hands on waist. Bending and bowing of the body. The exercise is performed 8-10 times. The energetic movement. When straightening - breath, bending exhale.

Exercise 8. Standing sideways to the chair, to hold back, the other hand on the waist. Alternate sweeps straight leg forward, with the greatest possible tour. Swing legs to be combined with the exhalation. Runs 4-6 times.

Exercise 9. Standing, feet apart, hands at sides. Bending the body forward, touch right brush left toe of the feet, the other hand is allotted up. To return to the original position. Tilt combined with exhalation, by straightening the breath by 4-6 times.

Exercise 10. Walking the quiet breathing of the average depth of 1-2 minutes

Exercise 11. Standing, hands in a fist and lowered: (a) bending of the arms at the elbows with the power and extension of their diverting ago, with possibly large rectification and voltage and delay in the stress state within 2-3 C. Standing, hands on waist; b) proprietary with subsequent lifting in socks and tension legs. The exercise is performed 4-6 times with possibly large rectification and voltage and delay in the stress state within 2-3 C.

Exercise 12. Sitting on the edge of the chair. In the raised position and bent knee leg to make alternate shaking the hands of the calf muscles and thighs. Reduce muscle tension 1-2 minutes

Exercise 13. Led is on the edge of the chair, straight legs divorced. Pinch open and direct the hands and feet. When breeding breath, when the note - exhale. Is 4-8 times.

Exercise 14. Standing. The quiet walk with the transition to the rhythmic quiet running (Jogging) on the spot or moving. For fatigue to go on a peaceful walk with the breath of the average depth of 2-5 minutes

Exercise 15. Lying on the Mat. Simultaneous lifting of the body and legs on the exhale 4-6 times. Arms and legs should be straight, to keep the balance.

Exercise 16. Lying on the Mat, the emphasis brushes the floor. Cross movement straight leg - scissors 4-8 times. Breathing is not to delay.

Exercise 17. With a quick straightening of the legs to move into a sitting position, then to lie down. You can help stroke 4-6 times.

Exercise 18. Lying on your back, legs bent. Calm breathing 4-6 times.

Exercise 19. Lying on his back, hands diluted with emphasis brushes the floor. With the rotation of the pelvis to the left to bend the legs, rotate the pelvis with legs crossed to the right and stretch the legs. To repeat such a circular motion feet 3-6 times in each direction alternately. Hands not off the floor. Breathing is not to delay.

Exercise 20. Lying on your back, arms and legs separated. Alternate turns the body right and left laying one hand to the other. Feet are not slipping. When divorced hands - breath, turning exhale. Performed 3-6 times.

Exercise 21. Lying on your back, arms along the body: a) turn on your left side; b) to turn on the right side; C) switch to lying on his stomach; to kneel; d) to move in a standing position; (e) walking on the spot with high flexion of the hips and the movement of the hand - 20-30 steps; g) to sit on the Mat; C) lie on your back, relaxing breath. The whole complex repeat 3-4 times.

Exercise 22. Standing. Walking the quiet breathing of the average depth of 1-2 minutes

Exercise 23. Standing, feet apart on the width of the foot, hands on waist. Circular motion of the pelvis, right and left 6-8 times. Breathing is not to delay.

Exercise 24. Standing with legs wide apart, hands in front of chest. Alternately bending the legs with the transfer to it of gravity of the body with stretching hand to toe of the bent leg. 4-6 times in each direction. The other leg is straight. When straightening - breath, when the tilt - exhale.

Exercise 25. Standing, feet apart at shoulder width, hands on waist. Circular head movements by 4-10 times in each direction.

Exercise 26. Standing, feet apart at shoulder width, hands on waist. Bend trunk to the right, pulling the left arm up-breath. Return to starting position - exhale. 4-6 times alternately.

Exercise 27. The same hands to the shoulders. Circular motion of the brushes with the maximum excursion in the shoulder joints, when breeding - breath during the mixing and retraction of the wall is Iwata - exhalation. Breathing deep.

Exercise 28. Standing. A peaceful walk and breath the average depth. The reduction of the total load for 1-2 minutes

3. Fractional exercise during the day

Sick AG I-II degree with MS who have had blood clots in the eye, is sick with a number of related disorders, primarily the cardiovascular system. This circumstance limits the simultaneous application of a high physical load during morning exercises, as well as in the main lesson, curative gymnastics. This is why increasing the physical activity of persons suffering from hypertension I-II degree when MS after thrombosis of vessels of the eye, it must be done by the distribution of physical activity in small doses throughout the day. This method of increasing physical activity in these patients should be considered as a method of fractional loads.

Depending on the conditions of real life in patients with arterial hypertension I-II degree with MS who have had blood clots in the eye with various degree of abdominal obesity, you can recommend various exemplary embodiments of the fractional loads to increase physical (motor) activity during the day.

Option 1

Exercise 1. Sitting - dilute the elbows to the sides, inhale, extend hands forward voltage exhale, 4-6 times.

Exercise 2. Sit - to stand with what ragiba corps and get - 8-10 times.

Exercise 3. Sitting mimicking the movements of a boxer with possibly a large turn of the body is 10-12 times.

Option 2

Exercise 1. Standing - walking with high flexion in the hip - 16-30 times.

Exercise 2. Standing - circular head movements to the right and left - 3-8 times in each direction.

Exercise 3. Standing legs apart widely imitated the movements of Costa - 10-12 times.

Exercise 4. Sitting - transition into the standing - 10-12 times.

Option 3

Exercise 1. The quiet walk - 1 min

Exercise 2. Walking fast - 1 minute

Exercise 3. Walking with high flexion of the hips and alternate wave of the hands 20-30 times.

Exercise 4. Walking the quiet breathing of 1-2 min; quiet running on the spot or move around the room - 2-5 minutes

Option 4

Walk the pedestrian varying length.

Option Fizicheskii work in different ways and with different duration depending on the conditions (cleaning, home services, cleaning, gardening work, and others).

The third component of the proposed method - the purpose of pioglitazone 30 mg 1 time per day, fourth - amlodipine 10 m 1 time per day at the same time.

The introduction of this method of correction functions of blood vessels in patients with arterial hypertension I-II degree with MS who have had blood clots in the eyes, into practice will allow R is sewing a number of pressing socio-economic problems. Effective correction of these patients will reduce these patients the period of temporary disability, prevent strokes, heart attacks and re-thrombosis of vessels of the eyes, to reduce the number of outputs on disability and reduce mortality among this group of patients.

Example 1. Patient S., 56, 72 kg, body mass index 29,8 kg/m2suffering from arterial hypertension of I degree with metabolic syndrome for 7 years, underwent 2 weeks ago thrombosis eyes, not systematically treated, examined while in ophthalmic hospital about thrombosis eyes. The patient was taken blood and investigated for the above scheme assessment IAAS, ISAAC and IFASS and calculating the total antithrombotic potential of the vessels.

The patients were identified expressed signs of oppression antithrombotic function of the vascular wall. IAASS was 1.06, ISAAC 1.07 and IPASS 1,09. Overall antithrombotic potential of vessels amounted XBi oops=0,054. The patient was assigned to the medical complex of low-calorie diet (1872,0 kcal.), dosed physical activity, pioglitazone 30 mg 1 time per day and amlodipine 10 mg 1 time per day. The study of the functions of the vascular wall were performed monthly. After 4 months the body weight was 67 kg, body mass index of 27.8 kg/m2And the ACC was 0,54, ISAAC 1,41 and IPASS 1,51, normalization of total antithrombotic potential vessels (XBi oops=0,208). Further sometimes imperfect adherence to patient data recommendations in terms of diet and exercise helped to support in next investigated parameters antithrombotic activity of vessels in normal limits.

Example 2. Patient M, 50, 82 kg, BMI of 31.2 kg/m2suffering from arterial hypertension of II degree with metabolic syndrome for 6 years, underwent 2 weeks ago thrombosis eyes, not systematically treated, examined while in ophthalmic hospital about thrombosis. The patient was taken blood and investigated for the above scheme assessment IAAS, ISAAC and IFASS and calculating the total antithrombotic potential of the vessels.

The patients were identified expressed signs of oppression antithrombotic function of the vascular wall. IAASS was 1,08, ISAAC 1,10 and IFAS to 1.15. Overall antithrombotic potential of vessels amounted XBi oops=0,063. The patient was assigned to the medical complex of low-calorie diet (1978,7 kcal), dosed physical activity, pioglitazone 30 mg 1 time per day and amlodipine 10 mg 1 time per day. The study of the functions of the vascular wall were performed monthly. After 4 mesmas body was 74 kg, a BMI of 28.1 kg/m2, IAASS was 1,58, ISAAC 1.40 and IPASS 1,52, normalization of total antithrombotic potential vessels (XBi oops=0,211). Further sometimes imperfect adherence to patient data recommendations in terms of diet and exercise helped to support in next investigated parameters antithrombotic activity of vessels in normal limits.

The use of the proposed correction method attenuation functions of blood vessels in Hematology, cardiology and endocrinology will help to avoid many of vascular complications in patients with arterial hypertension I-II degree in the metabolic syndrome who have had blood clots in the eye, they reduce the number of cases of temporary disability, to reduce the duration of hospitalization, reduce morbidity and mortality, excluding re-thrombosis of vessels of the eye.

Method for optimizing the activity of blood vessels in patients with arterial hypertension I-II degree with metabolic syndrome undergoing coronary vessels of the eye, including the use of individualized low-calorie diet, calculated (kcal) by the formula:
for women 18-30 years (0,0621×body weight (kg)+2,0357)×240,
31-60 years (0,342×body weight (kg)+3,5377)×240,
over 60 years of age (0,0377×body weight (kg)+2,7545)×240,
for men 18-30 years (0,0630×body weight (kg)+2,8957)×24,
31-60 years (0,0484×body weight (kg)+3,6534)×240,
over 60 years of age (0,0491×body weight (kg)+2,4587)×240,
dosed physical activity, which includes morning hygienic gymnastics, medical gymnastics and fractional exercise during the day, the introduction of pioglitazone 30 mg 1 time per day and amlodipine 10 mg 1 time a day at the same time for 4 months.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to a stable trehalose-stabilised formulation of amorphous perindopril erbumine, a method for preparation thereof consisting in the fact that a perindopril erbumine hydrate is dissolved in water or a mixture of water and alcohol; an alkaline stabiliser solution and inert ingredients is added to this solution for producing a granulate, dried in vacuum or in air flow at 40°C and less to be granulated to produce granulate.

EFFECT: formulations have higher stability.

16 cl, 7 dwg, 1 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: invention relates to complex immunomodelling treatment of patients with chronic heart failure (CHF). For this purpose to patients with CHF of II-IV functional classes according to NYHA and LV ejection fraction less than 45% at the background of conventional complex therapy, which includes application of diuretics, vasodilatators, cardiac glycosides, inhibitors of angiotensin-converting enzyme, additionally introduced is carvedilol in dose 12.5-50 mg/day. Introduction is performed in two intakes in equal parts for 12 months.

EFFECT: reduction of cytokine activity and syndrome correction of secondary immunodeficiency, which reduces severity of tissue affection and improves microcirculation and central hemodynamics, reduction of CHF severity and prevention of heart remodeling in said group of patients.

2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I) given below or pharmaceutically acceptable salts thereof:

[where: each of X, Y, Z and W independently denotes a methane group which optionally contains substitutes selected from a group of substitutes α, or a nitrogen atom (except when all elements X, Y, Z and W denote a methane group which optionally contain substitutes selected from the group of substitutes α); A denotes -(C(R3)(R4))m1-; B denotes -O-; D denotes -C(O)-; m1 equals 0; Q denotes a methane group or a nitrogen atom; R denotes a group of formula (II)

, where R6 denotes a lower alkyl group; R7 and R8, together with the nitrogen atom with which they are bonded, form a 5-6-member nitrogen-containing aliphatic heterocyclic group; and where the group of substitutes α includes the following substitutes. Group of substitutes α: halogen atom, hydroxyl group, lower alkyl group, alkoxyl group (said group can be substituted with a cycloalkyl group), amino group, mono- or disubstituted lower alkylamino group, aryl group (said group can be substituted with a halogen atom, a -SO2CH3 group), aryloxy group (said group can be substituted with a halogen atom), heteroaryl group, where 'heteroaryl group' denotes a 5- or 6-member monocyclic saturated or unsaturated group containing 1-2 heteroatoms selected from an oxygen atom or a nitrogen atom (said group can be substituted with an alkoxyl group, alkyl group). The invention also relates to a histamine 3 receptor antagonist, histamine 3 receptor inverse agonist, a prophylactic or medicinal agent, as well as a pharmaceutical composition.

EFFECT: obtaining novel biologically active compounds having histamine H3 receptor antagonist or inverse agonist action.

15 cl, 57 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and can be used for correction of vessel wall dysfunctions in patients with arterial hypertension (AH) of III degree with metabolic syndrome (MS), who had eye vessel thrombosis. For this purpose, at the background of individually selected hypocaloric diet and dosed physical exercise medications pioglitazone, lisinopril and amlodipine are introduced. Hypocaloric diet is calculated in kcal by formula: for women of 18-30 years - (0.0621 × body weight, kg + 2.0357) × 240, 31-60 years - (0.342 × body weight, kg + 3.5377) × 240, over 60 years - (0.0377 × body weight, kg + 2.7545) × 240, for men of 18-30 years - (0.0630 × body weight, kg + 2.8957) × 240, 31-60 years - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years - (0.0491 × body weight, kg +2.4587) × 240. Dosed physical exercise includes morning hygienic gymnastics, exercise therapy and dosed physical exercises during the day. Medication pioglitazone is introduced in dose 30 mg 1 time per day, lisinipril in dose 10 mg 1 time per day and amlodipine 10 mg 1 time per day at the same time of the day. Treatment is carried out for 4 months.

EFFECT: method ensures correction of attenuation of vessel wall functions in patients with AH of III degree with MS, after eye vessel thrombosis during 4 months and makes it possible to avoid vascular complications in such patients.

1 dwg, 1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula , where R3 has any

of the formulae , where R1 is selected from

,

where each R2 independently denotes hydrogen, halogen, C1-C8alkyl, C1-C8alkoxy- C1-C8alkyl, C1-C8alkoxy; R4 denotes a five- or six-member monocyclic ring system, having two heteroatoms selected from O, N and S, such as pyrazinyl, isoxazole or thiazolyl, each of which can be optionally substituted with one or more of the following substitutes: C1-C8alkyl or C1-C8alkoxy; R5 and R6 independently denote hydrogen or C1-C8alkyl; R7 and R8 together form a cyclopentyl ring; R9 independently denotes C1-C8alkyl; R9a independently denotes C1-C8alkylcarbonyl or phenylcarbonyl; R10 denotes hydrogen; R11 independently denotes C1-C8alkyl or C1-C8alkoxy; R12 denotes hydrogen or -COOR17; R13 independently denotes hydrogen, phenyl and a 6-member heteroaryl containing one heteroatom selected from N; R17 denotes hydrogen; R23 denotes (a) C1-C8alkyl, phenyl, a 5-member heteroaryl containing 1-2 heteroatoms selected from S and N, where any phenyl or heteroaryl residue is optionally substituted with a halogen, C1-C8alkyl or C1-C8alkoxy; R24 denotes C1-C8alkyl; R27 denotes H, C1-C8alkyl, C1-C8alkoxy, O-phenyl, S-phenyl; R29 denotes -(CH2)w-COOR17; where w=0; R31 denotes hydrogen; and pharmaceutically acceptable salts thereof. The invention also relates to a method of producing the disclosed compounds, a pharmaceutical composition, having dual acting ATI and ETA receptor antagonist properties, containing the disclosed compound as an active component, use of the compound in preparing a medicinal agent and methods of treating arterial hypertension.

EFFECT: high effectiveness of the compounds.

8 cl, 1 dwg, 39 ex

FIELD: chemistry.

SUBSTANCE: invention describes methods of purifying lercanidipine hydrochloride, which employ binary systems of an alcohol-containing solvent such as methanol or an aliphatic ester-containing solvent such as isopropylacetate. Described also is lercanidipine hydrochloride in polymorphous form V, synthesis methods thereof, as well as a pharmaceutical composition for treating hypertension containing lercanidipine hydrochloride in polymorphous form V.

EFFECT: high efficiency owing to use of cheap reagents, low amount of wastes, as well as obtaining clean lercanidipine hydrochloride.

20 cl, 4 ex, 1 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical field and deals with composition which possesses antagonistic activity with respect to endothelial receptors, which includes:

a) compound of formula or its pharmaceutically acceptaqble salt, solvate, hydrate or morphological form, b) filler, which consists of lactose monohydrate with monocrystalline cellulose; c) substance which ensures decomposition, which consists of sodium salt of starch glycolate or combination of sodium salt of starch glycolate and polybinylpyrrolodone; d) surface-active substance, consisting of polysorbate, in total amount from 0.1 to 3 wt % in terms of entire weight of pharmaceutical composition; and e) lubricating substance consisting of magnesium stearite.

EFFECT: invention provides stable pharmaceutical composition, which possesses favourable pharmacokinetic profile.

6 cl, 39 ex, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to stable solid medication, containing olmesartan medoxomil and amlodipine or its pharmaceutically acceptable salt. Said solid medication is, in fact, free of reducing sugars. Stable solid medication optionally can additionally contain hydrochlortiazide or its pharmacologically acceptable salt. Medicinal form is intended for treatment or prevention of diseases caused by hypertension.

EFFECT: solid medicinal form in accordance with invention has improved solubility properties in comparison with lactose-containing composition.

42 cl, 2 dwg, 4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and deals with correction of functions of vascular walls in patients with arterial hypertension of I-II degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose indices of anti-aggregate, anti-coagulant and fibrinolytic activity of vascular wall are determined. On the basis of said indices calculated is total anti-thrombotic potential of vessels and if its value is 0.069 and lower, complex treatment, including application of individually selected hypocaloric diet, dosed physical load, pioglitazone 30 mg 1 time per day and valsartan 160 mg 1 time per day in the morning during 4 months, is administered.

EFFECT: complex of drug and non-drug therapy in combination with empirically selected duration of treatment ensures correction of functions of vascular wall and, thus, reduction, of risk of thrombotic complications in said group of patients due to potentiation of therapeutic effect of separate components of therapeutic complex.

1 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and deals with correction of functions of vascular walls in patients with arterial hypertension of III degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose indices of anti-aggregate, anti-coagulant and fibrinolytic activity of vascular wall are determined. On the basis of said indices calculated is total anti-thrombotic potential of vessels and if its value is 0.069 and lower, complex treatment, including application of individually selected hypocaloric diet, dosed physical load, pioglitazone 30 mg 1 time per day and valsartan 80 mg 1 time per day in the morning and amlodipine 10 mg 1 time per day during 4 months, is administered.

EFFECT: complex of drug and non-drug therapy in combination with empirically selected duration of treatment ensures correction of functions of vascular wall and, thus, reduction, of risk of thrombotic complications in said group of patients due to potentiation of therapeutic effect of separate components of therapeutic complex.

1 ex, 1 dwg

FIELD: veterinary science.

SUBSTANCE: invention refers to a composition including alginate containing high concentration of mannuronic acid and a polycation of a polydispersity index less than 1.5. The composition is especially suitable for manufacturing of biologically compatible microcapsules containing live cells for allo- or xenografting.

EFFECT: microcapsules are more durable and can keep their structural and functional integrity for a long period of time as compared with common alginate microcapsules.

57 cl, 2 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: invention relates to complex immunomodelling treatment of patients with chronic heart failure (CHF). For this purpose to patients with CHF of II-IV functional classes according to NYHA and LV ejection fraction less than 45% at the background of conventional complex therapy, which includes application of diuretics, vasodilatators, cardiac glycosides, inhibitors of angiotensin-converting enzyme, additionally introduced is carvedilol in dose 12.5-50 mg/day. Introduction is performed in two intakes in equal parts for 12 months.

EFFECT: reduction of cytokine activity and syndrome correction of secondary immunodeficiency, which reduces severity of tissue affection and improves microcirculation and central hemodynamics, reduction of CHF severity and prevention of heart remodeling in said group of patients.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention represents application of composition, which includes protein material, where said protein material provides, at least, 24% of energy value of composition (en.%) and, at least, 12 wt % of all protein material is represented by leucine, for preparation of medication for treatment of subject with obesity.

EFFECT: extension of assortment of compositions, efficient for treatment of obesity.

35 cl

FIELD: medicine.

SUBSTANCE: claimed are method of reducing in circulating blood of LDL-cholesterol, triglycerides, total cholesterol and their mixtures, including introduction of efficient amount of one or more phosphate derivatives of one or more electron-transfer agents, which represent monotocopheryl phosphate, dotocopheryl phosphate, monotocotrienyl phosphate, ditocotrienyl phosphate and their mixtures, their application for relief of symptoms, treatment and/or prevention of disease, selected from group which consists of chronic renal failure, primary and secondary hyperemias and dislipemia, retinopathy, enlargement of liver and spleen, xanthomas and their combinations by reduction of lipid content in circulating blood.

EFFECT: reduction under action of claimed tocopherylphosphates of levels of total cholesterol, LDL in mice and reduction in them of atherosclerotic lesions, in people - improvement of dislipidemia state and increase of HDL cholesterol in comparison with tocopherol acetate.

5 cl, 3 dwg, 5 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I) given below or pharmaceutically acceptable salts thereof:

[where: each of X, Y, Z and W independently denotes a methane group which optionally contains substitutes selected from a group of substitutes α, or a nitrogen atom (except when all elements X, Y, Z and W denote a methane group which optionally contain substitutes selected from the group of substitutes α); A denotes -(C(R3)(R4))m1-; B denotes -O-; D denotes -C(O)-; m1 equals 0; Q denotes a methane group or a nitrogen atom; R denotes a group of formula (II)

, where R6 denotes a lower alkyl group; R7 and R8, together with the nitrogen atom with which they are bonded, form a 5-6-member nitrogen-containing aliphatic heterocyclic group; and where the group of substitutes α includes the following substitutes. Group of substitutes α: halogen atom, hydroxyl group, lower alkyl group, alkoxyl group (said group can be substituted with a cycloalkyl group), amino group, mono- or disubstituted lower alkylamino group, aryl group (said group can be substituted with a halogen atom, a -SO2CH3 group), aryloxy group (said group can be substituted with a halogen atom), heteroaryl group, where 'heteroaryl group' denotes a 5- or 6-member monocyclic saturated or unsaturated group containing 1-2 heteroatoms selected from an oxygen atom or a nitrogen atom (said group can be substituted with an alkoxyl group, alkyl group). The invention also relates to a histamine 3 receptor antagonist, histamine 3 receptor inverse agonist, a prophylactic or medicinal agent, as well as a pharmaceutical composition.

EFFECT: obtaining novel biologically active compounds having histamine H3 receptor antagonist or inverse agonist action.

15 cl, 57 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to endocrinology, and deals with reduction of glycemia and insulin-resistance level in patients with type 2 diabetes mellitus (DM). For this purpose for 2 months performed is pharmacotherapy, including introduction of januvia in dose 100 mg/day, metformin in dose 2000 mg/day, chromium picolinate in dose 1000 mcg/day. From the third day of pharmacotherapy administered is complex of physical exercises in form of dosed walking on treadmill in mode of step-load: first day - rate 3 km/hour, load duration - 2 min, second day - rate 4.6 km/hour, load duration - 1 min, third day: rate 4.8 km/hour, load duration - 2 min, fourth day: rate 5 km/hour, duration - 3 min, fifth day - rate 5.2 km/hour, duration - 4 minutes. After that, intensity of load is reduced in reverse order, with total duration of dosed load to 15 min and distance length - to 1220 m.

EFFECT: complex treatment ensures efficient reduction of glycemia level in patients with type 2 DM in stage of decompensation without application of insulin therapy.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and can be used for correction of vessel wall dysfunctions in patients with arterial hypertension (AH) of III degree with metabolic syndrome (MS), who had eye vessel thrombosis. For this purpose, at the background of individually selected hypocaloric diet and dosed physical exercise medications pioglitazone, lisinopril and amlodipine are introduced. Hypocaloric diet is calculated in kcal by formula: for women of 18-30 years - (0.0621 × body weight, kg + 2.0357) × 240, 31-60 years - (0.342 × body weight, kg + 3.5377) × 240, over 60 years - (0.0377 × body weight, kg + 2.7545) × 240, for men of 18-30 years - (0.0630 × body weight, kg + 2.8957) × 240, 31-60 years - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years - (0.0491 × body weight, kg +2.4587) × 240. Dosed physical exercise includes morning hygienic gymnastics, exercise therapy and dosed physical exercises during the day. Medication pioglitazone is introduced in dose 30 mg 1 time per day, lisinipril in dose 10 mg 1 time per day and amlodipine 10 mg 1 time per day at the same time of the day. Treatment is carried out for 4 months.

EFFECT: method ensures correction of attenuation of vessel wall functions in patients with AH of III degree with MS, after eye vessel thrombosis during 4 months and makes it possible to avoid vascular complications in such patients.

1 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: patient is examined for an anti-Mueller hormone level. If its value is increased by 1/3 and less from an upper limit of normal, a positive menstrual response to treatment is predicted.

EFFECT: method allows for high-precise prediction of clinical effectiveness of metformin and/or weight loss therapy in PCOS patients, exhibits high sensitivity and specificity.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is application of beta-hydroxybutyrate or its salts in combination with other active substance or combination of active substances, selected from group, given in the invention formula, for preparation of medication, which possesses cytoprotective activity, including neuroprotective, cardioprotective, anti-ischemic, antihypoxic, antistress and adaptogenic activities, medication and method of prevention, relief and treatment by means of said medication. Demonstrated is synergic of medication components as cytoprotector in urgent states as it possesses complex impact on key links of pathogenesis of said diseases.

EFFECT: elaboration of medication which possesses cytoprotective activity.

24 cl, 3 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to endocrinology, and deals with treatment of patients with neuropathic and neuroischemic forms of "diabetic foot" syndrome. For this purpose at the first stage on both extremities injection of 0.25% Novocain is made in dose 50.0 ml into fascial compartment of common paroneal nerve in distal direction to upper musculo-peroneal canal. After 1-2 days as the second stage injections of 0.125% Novocain solution in amount 50.0 ml are repeated in turns into each extremity with interval 3-5 days, course containing 5-6 injections.

EFFECT: elaborated doses and mode of Novocain introduction provide possibility to preserve foot due to stopping purulent inflammation with absence of side effects.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and can be used for correction of vessel wall dysfunctions in patients with arterial hypertension (AH) of III degree with metabolic syndrome (MS), who had eye vessel thrombosis. For this purpose, at the background of individually selected hypocaloric diet and dosed physical exercise medications pioglitazone, lisinopril and amlodipine are introduced. Hypocaloric diet is calculated in kcal by formula: for women of 18-30 years - (0.0621 × body weight, kg + 2.0357) × 240, 31-60 years - (0.342 × body weight, kg + 3.5377) × 240, over 60 years - (0.0377 × body weight, kg + 2.7545) × 240, for men of 18-30 years - (0.0630 × body weight, kg + 2.8957) × 240, 31-60 years - (0.0484 × body weight, kg + 3.6534) × 240; over 60 years - (0.0491 × body weight, kg +2.4587) × 240. Dosed physical exercise includes morning hygienic gymnastics, exercise therapy and dosed physical exercises during the day. Medication pioglitazone is introduced in dose 30 mg 1 time per day, lisinipril in dose 10 mg 1 time per day and amlodipine 10 mg 1 time per day at the same time of the day. Treatment is carried out for 4 months.

EFFECT: method ensures correction of attenuation of vessel wall functions in patients with AH of III degree with MS, after eye vessel thrombosis during 4 months and makes it possible to avoid vascular complications in such patients.

1 dwg, 1 tbl, 1 ex

Up!